Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling.
Overview
Angina is discomfort or an anginal equivalent due to myocardial oxygen supply–demand mismatch. In chronic coronary disease, antianginal drugs reduce symptoms, while separate therapies—lipid lowering, antithrombotics when indicated, smoking cessation and risk-factor control—reduce cardiovascular events. Angina caused by acute coronary syndrome requires emergency assessment [1, 2].
Main mechanisms and classifications
- Beta blockers: metoprolol, bisoprolol and others reduce heart rate and myocardial contractility, lowering oxygen demand.
- Calcium-channel blockers: amlodipine/dihydropyridines dilate arteries, whereas verapamil/diltiazem also slow heart rate and AV conduction.
- Organic nitrates: sublingual nitroglycerin for rapid relief, and isosorbide mono-/dinitrate or nitroglycerin patches for prevention; NO–cGMP signaling predominantly increases venous capacitance and reduces preload, with coronary vasodilator effects.
- Ranolazine: inhibits late inward sodium current, reducing intracellular sodium and calcium overload; antianginal without substantial direct lowering of heart rate or BP.
- Regional agents: nicorandil or trimetazidine have country-dependent indications and safety restrictions [1].
2023 AHA/ACC chronic coronary disease guideline
For chronic coronary disease with persistent angina, a beta blocker, calcium-channel blocker or long-acting nitrate is recommended for symptom relief. If symptoms continue, add a second agent from a different class. Ranolazine is recommended for persistent symptoms despite these therapies, and sublingual nitroglycerin is recommended for immediate short-term angina relief. Choice depends on heart rate, BP, LV function, comorbidity and symptoms [2].
Stable angina versus vasospastic angina
Beta blockers often help exertional angina but are generally not preferred as sole therapy for vasospastic (Prinzmetal) angina. Calcium-channel blockers are central to coronary spasm management, with nitrates added as needed. In severe LV systolic dysfunction, verapamil and diltiazem may worsen heart failure; use alternative therapies when appropriate [1, 2].
Nitrate interactions and patch timing
Ask specifically about phosphodiesterase-5 inhibitors such as sildenafil and tadalafil, and about riociguat. Combining these drugs with nitrates can cause profound hypotension. A long-acting nitrate patch prevents episodes and is unsuitable for acute relief. Continuous exposure can produce tolerance. A common patch schedule leaves 10–12 hours off each day, with timing individualised to the symptom pattern. [3, 4]
Ranolazine and drug interactions
Ranolazine is an option for persistent chronic angina and generally has little effect on resting heart rate or blood pressure. It is an extended-release maintenance treatment. It can prolong QT, and strong CYP3A inhibitors or inducers are contraindicated. The US label also contraindicates ranolazine in liver cirrhosis. Reducing the dose is insufficient to address that contraindication. Review the medication list and renal function when selecting it. [5, 2] Beta blockers can cause bradycardia; combining verapamil/diltiazem with beta blockade may cause AV block. Pregnancy and lactation decisions require specialist evaluation [1].
Emergency symptoms and follow-up
New or worsening rest chest pain, syncope, breathlessness or symptoms not resolving promptly with prescribed rescue treatment require emergency care. Persistent symptoms despite antianginal medication should prompt evaluation of diagnosis, adherence, coronary anatomy and potential revascularization as appropriate [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC multisociety guideline for the management of patients with chronic coronary disease. Circulation. 2023;148:e9–e119. doi:10.1161/CIR.0000000000001168. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2023.04.003
- National Library of Medicine. Nitrostat (nitroglycerin sublingual tablets). DailyMed prescribing information. View source.
- National Library of Medicine. Nitroglycerin transdermal delivery system. DailyMed prescribing information. View source.
- National Library of Medicine. Ranolazine extended-release tablets. DailyMed prescribing information. View source.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.